Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Ideaya Biosciences Inc (IDYA)

Ideaya Biosciences Inc (IDYA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
MarketBeat.com
IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial Data MarketBeat - Sun May 17, 11:05PM CDT

IDEAYA Biosciences (NASDAQ:IDYA) said its lead oncology program remains on track for a regulatory submission after reporting positive top-line data in first-line metastatic melanoma, while also highlighting...

IDYA : 29.10 (-1.49%)
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update PR Newswire - Tue May 5, 5:00AM CDT

SOUTH SAN FRANCISCO, Calif. , May 5, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, provided a business update and announced financial...

IDYA : 29.10 (-1.49%)
IDEAYA's Darovasertib Approval Assumption Now Collides With What Revenue Actually Looks Like—Or Doesn't Barchart - Mon May 4, 4:15PM CDT

Barchart Research What to Expect from IDYA Earnings IDYA Generated May 4, 2026 Current Price $28.90 EPS Estimate $$-1.07 Consensus Rating Strong Buy Average Move 4.38% IDEAYA's Darovasertib Approval Assumption...

IDYA : 29.10 (-1.49%)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Fri May 1, 5:00AM CDT

SOUTH SAN FRANCISCO, Calif. , May 1, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

IDYA : 29.10 (-1.49%)
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma PR Newswire - Tue Apr 21, 9:15AM CDT

SOUTH SAN FRANCISCO, Calif. , April 21, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have been selected for a...

IDYA : 29.10 (-1.49%)
American flag on NY Stock Exchange by Chameleonseye via iStock
Stocks Settle Higher in Hopes for an Agreement to End the Iran War Barchart - Mon Apr 13, 3:37PM CDT

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +1.02%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.63%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.06%. June E-mini S&P...

IDYA : 29.10 (-1.49%)
AVGO : 414.14 (-0.10%)
INTU : 319.94 (+4.19%)
SNDK : 1,478.69 (-4.12%)
SRE : 92.80 (+1.37%)
$IUXX : 29,481.64 (+0.42%)
ZNM26 : 109-080s (+0.01%)
ESM26 : 7,491.00s (+0.33%)
QCOM : 238.16 (+11.60%)
STX : 812.73 (+0.28%)
BBY : 61.63 (+0.78%)
$DOWI : 50,579.70 (+0.58%)
Nasdaq Times Square by Lucky Photographer via iStock
Stocks Recover as Oracle Leads Software Companies Higher Barchart - Mon Apr 13, 10:09AM CDT

The S&P 500 Index ($SPX ) (SPY ) today is up +0.09%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.39%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.16%. June E-mini S&P futures (ESM26...

ALK : 41.34 (+0.61%)
UAL : 99.96 (+0.32%)
IDYA : 29.10 (-1.49%)
INTU : 319.94 (+4.19%)
SNDK : 1,478.69 (-4.12%)
$IUXX : 29,481.64 (+0.42%)
ZNM26 : 109-080s (+0.01%)
ESM26 : 7,491.00s (+0.33%)
NCLH : 16.30 (-1.03%)
BBY : 61.63 (+0.78%)
$DOWI : 50,579.70 (+0.58%)
SPY : 745.64 (+0.39%)
IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma PR Newswire - Mon Apr 13, 5:00AM CDT

SOUTH SAN FRANCISCO, Calif. , April 13, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company, and Servier, an independent international pharmaceutical...

IDYA : 29.10 (-1.49%)
IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026 PR Newswire - Fri Apr 10, 3:05PM CDT

SOUTH SAN FRANCISCO, Calif. , April 10, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company, today announced plans to issue a joint IDEAYA and Servier...

IDYA : 29.10 (-1.49%)

Barchart Exclusives

Can November Soybeans Challenge Contract Highs? Strong Crush Demand and Seasonal Strength Say It's Possible Barchart - Sat May 23, 3:37PM CDT
November soybeans may be setting up one of the better seasonal opportunities in ag markets right now. Record crush demand, bullish technicals, and a weather market season are all lining up at the same time.MRCI research also shows Nov beans closed higher in this seasonal window 12 of the past 15 years, with 8 of those years seeing no daily closing drawdowns.That kind of historical consistency gets traders' attention! Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.